Opinion|Videos|December 10, 2024
Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
- Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the mechanism of action of Vowst, and how does this therapy differ from previously used therapies in recurrent C difficile infections?
- What is the key data that led to the FDA-approval of Vowst for recurrent C difficile infection?
- Who are the target patient populations for Vowst?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population
3
FDA Approves Durvalumab With FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Cancer
4
Patients Face New Care Complexities as DTC Options Expand
5
